Attached files
| file | filename |
|---|---|
| EX-10.1 - LOGIQ, INC. | v206356_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 22, 2010 (December 17,
2010)
SINOBIOMED
INC.
(Exact
name of registrant as specified in its charter)
Commission
File Number 333-128399
|
Delaware
|
20-1945139
|
|
|
(State or other jurisdiction
of incorporation)
|
(I.R.S. Employer
Identification No.)
|
Room
4304, 43/F China Resources Building
26
Harbour Road, Wan Chai
Hong
Kong HKSAR
(Address
of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code: 011-852-2511-0238
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
ITEM
1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
December 17, 2010, Sinobiomed Inc. (the “Company”) entered into a stock purchase
and sale agreement (the “Purchase and Sale Agreement”) with China Nonferrous
Metals Resource Geological Survey Inc. (“China Nonferrous”), a British Virgin
Islands company and Wanxin Bio-Technology Limited (“Wanxin”), the Company’s
wholly-owned British Virgin Islands subsidiary, pursuant to which the Company
agreed to sell 100% of its equity interest in Wanxin to China Nonferrous for an
aggregate sale price of $200,000.
The
foregoing description of the terms of the Asset Purchase Agreement is qualified
by reference to the Purchase and Sale Agreement which is attached as
Exhibit 10.1 hereto.
(d) Exhibits
|
Exhibit No.
|
Description
|
|
|
10.1
|
Purchase
and Sale Agreement, dated December 17, 2010, between Sinobiomed, Inc.,
China Nonferrous Metals Resource Geological Survey Inc. and Wanxin
Bio-Technology Limited.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
SINOBIOMED
INC.
|
|||
|
By:
|
/s/
George Yu
|
||
|
Name:
|
George
Yu
|
||
|
Title:
|
Chief
Executive Officer
|
||
Date:
December 22, 2010
EXHIBIT
INDEX
|
Exhibit No.
|
Description
|
|
|
10.1
|
Purchase
and Sale Agreement, dated December 17, 2010, between Sinobiomed, Inc.,
China Nonferrous Metals Resource Geological Survey Inc. and Wanxin
Bio-Technology Limited.
|